Predictors of Immunotherapy Efficacy in Metastatic Non-Small Cell Lung Cancer: Lung Immune Prognostic Index and Immune-Related Toxicity

Overview

Journal World J Oncol

Specialty Oncology

Date 2024 Mar 28

PMID 38545481

Authors

Alba Moratiel Pellitero

Maria Zapata Garcia

Marta Gascon Ruiz

Jose Miguel Arbones-Mainar

Rodrigo Lastra Del Prado

Dolores Isla

Affiliations

Soon will be listed here.

Abstract

Background: Immune checkpoint inhibitors (ICIs) have been proposed as the standard first-line and subsequent treatment for metastatic non-small cell lung cancer (NSCLC). This study analyzed whether patients with good lung immune prognostic index (LIPI) have a better response to ICIs and the relationship between immune-related adverse events (irAEs) and response in clinical practice.

Methods: This was an observational, retrospective, single-center study. Patients with stage IV NSCLC between 2016 and 2021 were included in the study. Toxicity was assessed according to The Common Terminology Criteria for Adverse Events. Response assessment was performed according to RECIST 2.0 and immuno-related criteria. Descriptive and survival analyses were conducted. Degree of toxicity and response to treatment (based on treatment and histology) were assessed. LIPI and response were assessed. LIPI included dNLR (absolute neutrophil count/(white blood cell count - absolute neutrophil count)) ≥ 3 and lactate dehydrogenase (LDH) greater than the upper limit of normal. Patients were stratified into good (G), intermediate (I), and poor (P) prognostic groups.

Results: A total of 168 patients were included (130 men and 38 women, mean age 64.3 years). ICI use in the first- or second-line treatment was 65% and 35%, respectively. Fifteen (9%) patients showed complete response (CR), 50 (30%) showed partial response (PR), 39 (22%) had stable disease (SD), 45 (28%) had progressive disease (PD), and 19 (11%) were not evaluated (NE). Patients with good prognostic LIPI (dNLR < 3 and normal LDH levels) showed a better response. Progression-free survival (PFS) was 19 months in G, 6 months in I, and 2 months in P. Overall survival (OS) was 27 months in G, 8 months in I, and 3 months in P. One hundred fourteen patients died (56% G, 76% I, 93% P). Patients with adenocarcinoma were 116 (77 with irAEs G1-4 (13 CR, 31 PR, 21 SD, eight PD, and four NE)), and without were 39 (three PR, six SD, 21 PD, and nine NE). Fifty-two patients had squamous carcinoma (27 with irAEs G1-4 (two CR, 12 PR, nine SD, and four PD)), and 25 did not (four PR, three SD, 12 PD, and six NE)). IrAEs appearance was observed in longer PFS (19 vs. 2 months) and OS (27 vs. 4 months; P < 0.0001).

Conclusions: LIPI was a positive predictor of response to ICI. The presence of irAEs is associated with a better immune response. In contrast, the absence of toxicity predicted a worse prognosis.

References

Zer A, Sung M, Walia P, Khoja L, Maganti M, Labbe C . Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018; 19(5):426-434.e1. DOI: 10.1016/j.cllc.2018.04.008. View

Prelaj A, Tay R, Ferrara R, Chaput N, Besse B, Califano R . Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. Eur J Cancer. 2018; 106:144-159. DOI: 10.1016/j.ejca.2018.11.002. View

Naidoo J, Zhang J, Lipson E, Forde P, Suresh K, Moseley K . A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events. J Natl Compr Canc Netw. 2019; 17(6):712-720. DOI: 10.6004/jnccn.2018.7268. View

Suh K, Kim S, Kim Y, Kim M, Keam B, Kim T . Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. Cancer Immunol Immunother. 2017; 67(3):459-470. PMC: 11028357. DOI: 10.1007/s00262-017-2092-x. View

Liu H, Yang X, Yang X, Dong Z, Chen Z, Hong J . The Prediction Potential of the Pretreatment Lung Immune Prognostic Index for the Therapeutic Outcomes of Immune Checkpoint Inhibitors in Patients With Solid Cancer: A Systematic Review and Meta-Analysis. Front Oncol. 2021; 11:691002. PMC: 8496897. DOI: 10.3389/fonc.2021.691002. View

Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M . The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS One. 2018; 13(2):e0193018. PMC: 5814002. DOI: 10.1371/journal.pone.0193018. View

Peng Y, Li Q, Zhang J, Shen W, Zhang X, Sun C . Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors. Biosci Trends. 2018; 12(6):537-552. DOI: 10.5582/bst.2018.01246. View

Santoni M, Rizzo A, Mollica V, Matrana M, Rosellini M, Faloppi L . The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. Crit Rev Oncol Hematol. 2022; 170:103596. DOI: 10.1016/j.critrevonc.2022.103596. View

Xiong A, Xu J, Wang S, Zhong R, Lu J, Chu T . On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer. Front Immunol. 2023; 14:1173025. PMC: 10247997. DOI: 10.3389/fimmu.2023.1173025. View

10.

Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y . Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. J Thorac Oncol. 2017; 12(12):1798-1805. DOI: 10.1016/j.jtho.2017.08.022. View

11.

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D . Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 4(3):351-357. PMC: 5885829. DOI: 10.1001/jamaoncol.2017.4771. View

12.

Ortega-Franco A, Hodgson C, Raja H, Carter M, Lindsay C, Hughes S . Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index. Target Oncol. 2022; 17(4):453-465. DOI: 10.1007/s11523-022-00889-8. View

13.

Rizzo A, Cusmai A, Giovannelli F, Acquafredda S, Rinaldi L, Misino A . Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022; 14(6). PMC: 8945985. DOI: 10.3390/cancers14061404. View

14.

Ruiz-Patino A, Arrieta O, Cardona A, Martin C, Raez L, Zatarain-Barron Z . Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP). Thorac Cancer. 2019; 11(2):353-361. PMC: 6996989. DOI: 10.1111/1759-7714.13272. View

15.

Chen J, Wei S, Zhao T, Zhang X, Wang Y, Zhang X . Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB. Dis Markers. 2022; 2022:7137357. PMC: 9357262. DOI: 10.1155/2022/7137357. View

16.

Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A . Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer. 2018; 115:71-74. DOI: 10.1016/j.lungcan.2017.11.019. View

17.

Das S, Johnson D . Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019; 7(1):306. PMC: 6858629. DOI: 10.1186/s40425-019-0805-8. View

18.

Rizzo A . Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate. Br J Cancer. 2022; 127(8):1381-1382. PMC: 9553978. DOI: 10.1038/s41416-022-01929-w. View

19.

Pierro M, Baldini C, Auclin E, Vincent H, Varga A, Martin Romano P . Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score. Cancers (Basel). 2022; 14(20). PMC: 9600023. DOI: 10.3390/cancers14205078. View

20.

Narvaez J, Juarez-Lopez P, Lluch J, Narvaez J, Palmero R, Garcia Del Muro X . Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy. Autoimmun Rev. 2018; 17(10):1040-1045. DOI: 10.1016/j.autrev.2018.05.002. View